Q32 Bio Inc. (Nasdaq: QTTB), a US-based clinical stage biotechnology company, announced on Monday that it is joining the Russell 3000 Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the US market opening effective 1 July 2024.
Investment managers and institutional investors use Russell indexes for index funds and as benchmarks for active investment strategies. Lee Kalowski, Q32 Bio president and chief financial officer, said, 'We are pleased to be included in the Russell 3000 Index as we approach our anticipated milestones, progress our pipeline for severe autoimmune and inflammatory diseases, and continue to expand our shareholder base.'
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development